What is GLP-1 and why does it matter?
GLP-1 stands for glucagon-like peptide-1. It is an incretin hormone — a gut hormone released from L-cells in the intestinal lining in response to food intake. Its name comes from the fact that its amino acid sequence resembles a fragment of proglucagon, the precursor protein to glucagon, a different hormone that raises blood sugar.
When you eat, GLP-1 is released into the bloodstream within minutes. It serves several coordinated roles: it signals the pancreas to increase insulin secretion in a glucose-dependent manner (meaning it only drives insulin release when blood glucose is elevated), it suppresses glucagon (the hormone that raises blood sugar), it slows gastric emptying, and it signals the brain to reduce appetite.
The critical limitation of native GLP-1 is its extremely short half-life in the body — roughly one to two minutes before enzymes called dipeptidyl peptidase-4 (DPP-4) degrade it. This is pharmacologically inconvenient if you want to use the GLP-1 pathway therapeutically. The solution researchers arrived at was to develop modified versions of the peptide — GLP-1 receptor agonists — that are resistant to DPP-4 degradation and have half-lives measured in days rather than minutes.
What makes a drug a GLP-1 receptor agonist?
A GLP-1 receptor agonist is any compound that binds to the GLP-1 receptor and activates it — producing the same or similar downstream effects as native GLP-1, but with a longer duration of action.
These drugs are peptides in structure, meaning they are chains of amino acids. Because peptides are degraded in the gastrointestinal tract before absorption, most GLP-1 receptor agonists are administered by subcutaneous injection. A once-weekly injection cadence is now standard for several agents, made possible by structural modifications that slow their clearance from the body.
The GLP-1 receptor itself is a G-protein-coupled receptor (GPCR) expressed in multiple tissues: the pancreas, the gastrointestinal tract, the cardiovascular system, and critically, the central nervous system — including the hypothalamus and brainstem regions involved in energy homeostasis.
Native GLP-1 lasts one to two minutes; the engineered agonists resist DPP-4 and last about a week — that single change is what turns a fleeting gut signal into a once-weekly therapy.
How do GLP-1 receptor agonists reduce appetite and body weight?
The weight management effects of GLP-1 receptor agonists are driven by multiple converging mechanisms rather than a single pathway. Understanding each helps explain both the magnitude of effect seen in trials and why individual response varies.
Hypothalamic appetite suppression
GLP-1 receptors in the arcuate nucleus and other hypothalamic regions regulate hunger signals. When activated by GLP-1 receptor agonists, these receptors reduce the drive to eat by modulating the POMC/AgRP neuronal balance — the system that sets the “set point” for hunger and satiety. This is the mechanism that patients often describe as a reduced sense of food preoccupation.
Brainstem reward circuit modulation
GLP-1 receptors are also present in the mesolimbic reward system, including the nucleus accumbens, a region involved in food reward and craving. Activation here is associated with reduced hedonic eating — the drive to eat for pleasure beyond caloric need. Patients in trials often report reduced interest in previously preferred high-calorie foods, which may reflect this mechanism.
Gastric emptying delay
GLP-1 receptor agonists slow the rate at which the stomach empties food into the small intestine. This extends the physical and hormonal signals of satiation that follow a meal, reduces postprandial glucose spikes, and contributes to the feeling of fullness that patients report. The nausea that some people experience, particularly early in treatment, is largely attributable to this mechanism.
Insulin-glucagon balance
In patients with metabolic dysfunction, the glucose-dependent insulin secretion and glucagon suppression effects of GLP-1 receptor agonists help normalize postmeal blood sugar dynamics. This is the mechanism underlying their utility in managing blood sugar, though in the weight management context, the central appetite mechanisms tend to be the primary driver of body weight change.
How do semaglutide and tirzepatide differ within the class?
Semaglutide is a GLP-1 receptor agonist with about 94% amino acid sequence homology to native GLP-1, modified with a fatty acid chain and linker that enables albumin binding and dramatically extends its half-life to approximately one week. It targets only the GLP-1 receptor.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone, released from K-cells in the gut. By activating both GIP and GLP-1 receptors simultaneously, tirzepatide appears to produce synergistic effects on appetite regulation and fat metabolism beyond what GLP-1 receptor activation alone achieves. This dual mechanism is associated with the particularly robust weight management outcomes seen in the SURMOUNT trials.
Both semaglutide and tirzepatide are available as compounded preparations through licensed telehealth programs. Compounded versions are prepared in the USA by licensed 503A pharmacies — no hidden overseas supply chain. The active molecules are the same as those in the clinical trial literature; the compounded preparations themselves have not received separate FDA approval.
What are GLP-1 receptor agonists not?
Some important clarifications that get obscured in popular coverage:
- GLP-1 receptor agonists do not work by stimulating metabolism or burning more calories. Their primary mechanism is appetite and food intake reduction, not thermogenesis.
- They are not appetite suppressants in the traditional stimulant sense. They work through hormonal signaling, not the sympathetic nervous system pathways that stimulant-based appetite suppressants target.
- They are not a substitute for adequate protein intake and appropriate physical activity. Weight loss on GLP-1 programs includes lean mass loss as well as fat loss if diet and exercise are not managed deliberately.
- They are not permanent solutions on their own. The mechanism is active during treatment; most of the pharmacological effect dissipates when the medication is discontinued.
Why does GLP-1 therapy require clinician supervision?
GLP-1 receptor agonists require individualized management. Titration speed, dose, contraindication screening (personal or family history of medullary thyroid carcinoma or MEN2, pancreatitis history, gallbladder disease), and monitoring for relevant lab changes all require a licensed clinician’s involvement. Prescribing these medications without that oversight — as some unregulated online vendors attempt to facilitate — is both clinically inappropriate and legally questionable.
For those interested in clinician-supervised, compounded GLP-1 weight management, PepScribe offers compounded semaglutide and compounded tirzepatide programs, with medications prepared in the USA by licensed 503A pharmacies and prescriptions issued by licensed clinicians following a structured intake review.
Frequently asked questions
What is a GLP-1 receptor agonist?
A GLP-1 receptor agonist is a drug that binds to and activates GLP-1 receptors throughout the body. These drugs mimic the action of glucagon-like peptide-1 (GLP-1), a natural incretin hormone, but with a longer half-life that sustains their effects beyond what native GLP-1 can do.
How do GLP-1 receptor agonists reduce appetite?
GLP-1 receptors are present in the hypothalamus and brainstem regions that regulate hunger and satiety. When activated, they signal reduced food intake and increase the sensation of fullness. GLP-1 receptor agonists also slow gastric emptying, extending the sense of satiation after eating.
Is semaglutide a GLP-1 receptor agonist?
Yes. Semaglutide is a GLP-1 receptor agonist. It was originally developed for blood sugar management but is also studied and used for weight management in appropriate patients. Compounded semaglutide is prepared by licensed 503A pharmacies in the USA. Compounded preparations are not FDA-approved drugs — they are made under 503A compounding regulations and have not been separately approved by the FDA.
Is tirzepatide a GLP-1 receptor agonist?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual mechanism is associated with robust weight management effects in clinical trials.
Are GLP-1 receptor agonists FDA approved?
Several GLP-1 receptor agonists are FDA approved for specific indications. The compounded versions of semaglutide and tirzepatide available through telehealth providers like PepScribe are not themselves FDA-approved drugs — they are compounded in the USA by licensed 503A pharmacies under applicable regulations.
What are the main side effects of GLP-1 receptor agonists?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are typically most pronounced during dose escalation and often diminish as the body adapts. A clinician can help manage titration speed and adjunctive strategies to improve tolerability.